ID: ALA5219249

Max Phase: Preclinical

Molecular Formula: C20H23N5O4S

Molecular Weight: 429.50

Representations

Canonical SMILES:  CN1CCn2ncc(S(=O)(=O)NC(=O)Nc3c4c(cc5c3CCC5)CCC4)c2C1=O

Standard InChI:  InChI=1S/C20H23N5O4S/c1-24-8-9-25-18(19(24)26)16(11-21-25)30(28,29)23-20(27)22-17-14-6-2-4-12(14)10-13-5-3-7-15(13)17/h10-11H,2-9H2,1H3,(H2,22,23,27)

Standard InChI Key:  KWTMFTQOSIRXHO-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 429.50

Molecular Weight (Monoisotopic): 429.1471

AlogP: 1.46

#Rotatable Bonds: 3

Polar Surface Area: 113.40

Molecular Species: ACID

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 5.22

CX Basic pKa:

CX LogP: 1.97

CX LogD: 1.04

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.77

Np Likeness Score: -0.85

References

1. McBride C, Trzoss L, Povero D, Lazic M, Ambrus-Aikelin G, Santini A, Pranadinata R, Bain G, Stansfield R, Stafford JA, Veal J, Takahashi R, Ly J, Chen S, Liu L, Nespi M, Blake R, Katewa A, Kleinheinz T, Sujatha-Bhaskar S, Ramamoorthi N, Sims J, McKenzie B, Chen M, Ultsch M, Johnson M, Murray J, Ciferri C, Staben ST, Townsend MJ, Stivala CE..  (2022)  Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor.,  65  (21.0): [PMID:36279149] [10.1021/acs.jmedchem.2c01250]

Source

Source(1):

• Scientific Literature